Structural modifications of ICAM-1 cyclic peptides to improve the activity to inhibit heterotypic adhesion of T cells

Chemical Biology and Drug Design

Volumn 72, Issue 1, 2008, Pages 27-33

  Iskandarsyah, ^a,b   Tejo, Bimo A ^a   Tambunan, Usman S F ^b   Verkhivker, Gennady ^a   Siahaan, Teruna J ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

Mechanism based drug design; Peptide; Receptor and ligands (agonist antagonist); Structure based drug design

Indexed keywords

CYCLO(1,10)CYSTEINYLPROLYLARGINYLGLYCYLGLYCYLSERYLVALYLLEUCYLVALYLCYSTEINE HYDROXIDE; CYCLO(1,11)CYSTEINYLPROLYLARGINYLGLYCYLGLYCYLSERYLVALYLLEUCYLVALYLTHREONYLCYSTEINE HYDROXIDE; CYCLO(1,12)CYSTEINYLPROLYLARGINYLGLYCYLGLYCYLSERYLVALYLLEUCYLVALYLTHREONYLGLYCYLCYSTEINE HYDROXIDE; CYCLO(1,12)CYSTEINYLPROLYLGLYCYLGLYCYLSERYLVALYLLEUCYLVALYLTHREONYLGLYCYLCYSTEINE HYDROXIDE; CYCLO(1,12)LYSYLPROLYLARGINYLGLYCYLGLYCYLSERYLVALYLLEUCYLVALYLTHREONYLGLYCYLGLUTAMIC ACID HYDROXIDE; CYCLO(1,12)PENPROLYLARGINYLGLYCYLGLYCYLSERYLVALYLLEUCYLVALYLTHREONYLGLYCYLCYSTEINE HYDROXIDE; CYCLO(1,13)CYSTEINYLLYSYLPROLYLARGINYLGLYCYLGLYCYLSERYLVALYLLEUCYLVALYLTHREONYLGLYCYLCYSTEINE HYDROXIDE; CYCLO(1,8)CYSTEINYLPROLYLARGINYLGLYCYLGLYCYLSERYLVALYLCYSTEINE HYDROXIDE; CYCLOPEPTIDE; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ARTICLE; BIOLOGICAL ACTIVITY; CELL ADHESION; CONTROLLED STUDY; CYCLIZATION; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

ANTIGEN-PRESENTING CELLS; AUTOIMMUNE DISEASES; CELL ADHESION; DRUG DESIGN; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; PEPTIDES, CYCLIC; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 45449118958     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00676.x     Document Type: Article

References (41)

1. Grakoui A., Bromley S.K., Sumen C., Davis M.M., Shaw A.S., Allen P.M., Dustin M.L. (1999) The immunological synapse: a molecular machine controlling T cell activation. Science 285: 221 227.
2. Shier P., Ngo K., Fung-Leung W.P. (1999) Defective CD8+ T cell activation and cytolytic function in the absence of LFA-1 cannot be restored by increased TCR signaling. J Immunol 163: 4826 4832.
3. Rothlein R., Dustin M.L., Marlin S.D., Springer T.A. (1986) A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 137: 1270 1274.
4. Marlin S.D., Springer T.A. (1987) Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 51: 813 819.
5. Edwards C.P., Fisher K.L., Presta L.G., Bodary S.C. (1998) Mapping the intercellular adhesion molecule-1 and -2 binding site on the inserted domain of leukocyte function-associated antigen-1. J Biol Chem 273: 28937 28944.
6. Song G., Yang Y., Liu J.H., Casasnovas J.M., Shimaoka M., Springer T.A. et al. (2005) An atomic resolution view of ICAM recognition in a complex between the binding domains of ICAM-3 and integrin αLβ2. Proc Natl Acad Sci USA 102: 3366 3371.
7. Hermand P., Huet M., Callebaut I., Gane P., Ihanus E., Gahmberg C.G. et al. (2000) Binding sites of leukocyte β 2 integrins (LFA-1, Mac-1) on the human ICAM-4/LW blood group protein. J Biol Chem 275: 26002 26010.
8. Tian L., Kilgannon P., Yoshihara Y., Mori K., Gallatin W.M., Carpen O. et al. (2000) Binding of T lymphocytes to hippocampal neurons through ICAM-5 (telencephalin) and characterization of its interaction with the leukocyte integrin CD11a/CD18. Eur J Immunol 30: 810 818.
9. Ostermann G., Weber K.S., Zernecke A., Schroder A., Weber C. (2002) JAM-1 is a ligand of the β(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol 3: 151 158.
10. Qu A., Leahy D.J. (1995) Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, αLβ2) integrin. Proc Natl Acad Sci USA 92: 10277 10281.
11. Hogg N., Stewart M.P., Scarth S.L., Newton R., Shaw J.M., Law S.K. et al. (1999) A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1. J Clin Invest 103: 97 106.
12. Hogg N., Henderson R., Leitinger B., McDowall A., Porter J., Stanley P. (2002) Mechanisms contributing to the activity of integrins on leukocytes. Immunol Rev 186: 164 171.
13. Soleimani B., Wieczorek G., Katopodis A., Zenke G., George A.J., Hornick P.I. et al. (2007) Anti-LFA-1 monotherapy prevents neointimal formation in a murine model of transplant intimal hyperplasia. J Heart Lung Transplant 26: 724 731.
14. Go S., Fleischmann A., Lantz O., Cretolle C., Brousse N., Cerf-Bensussan N. et al. (2006) Anti-LFA-1 antibody postpones T-cell receptor triggering while preserving generation of regulatory T cells in T-cell receptor anti-HY transgenic mice. Transplantation 82: 119 126.
15. Blois S., Tometten M., Kandil J., Hagen E., Klapp B.F., Margni R.A. et al. (2005) Intercellular adhesion molecule-1/LFA-1 cross talk is a proximate mediator capable of disrupting immune integration and tolerance mechanism at the feto-maternal interface in murine pregnancies. J Immunol 174: 1820 1829.
16. Gottlieb A.B., Krueger J.G., Wittkowski K., Dedrick R., Walicke P.A., Garovoy M. (2002) Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 138: 591 600.
17. Papp K., Bissonnette R., Krueger J.G., Carey W., Gratton D., Gulliver W.P. et al. (2001) The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 45: 665 674.
18. Ke Y., Sun D., Zhang P., Jiang G., Kaplan H.J., Shao H. (2007) Suppression of established experimental autoimmune uveitis by anti-LFA-1alpha Ab. Invest Ophthalmol Vis Sci 48: 2667 2675.
19. Willenborg D.O., Staykova M.A., Miyasaka M. (1996) Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. J Immunol 157: 1973 1980.
20. Kobayashi Y., Kawai K., Honda H., Tomida S., Niimi N., Tamatani T. et al. (1995) Antibodies against leukocyte function-associated antigen-1 and against intercellular adhesion molecule-1 together suppress the progression of experimental allergic encephalomyelitis. Cell Immunol 164: 295 305.
21. Gordon E.J., Myers K.J., Dougherty J.P., Rosen H., Ron Y. (1995) Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 62: 153 160.
22. Kawai K., Kobayashi Y., Shiratori M., Sobue G., Tamatani T., Miyasaka M. et al. (1996) Intrathecal administration of antibodies against LFA-1 and against ICAM-1 suppresses experimental allergic encephalomyelitis in rats. Cell Immunol 171: 262 268.
23. Connolly M.K., Kitchens E.A., Chan B., Jardieu P., Wofsy D. (1994) Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen-1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy. Clin Immunol Immunopathol 72: 198 203.
24. Kakimoto K., Nakamura T., Ishii K., Takashi T., Iigou H., Yagita H. et al. (1992) The effect of anti-adhesion molecule antibody on the development of collagen-induced arthritis. Cell Immunol 142: 326 337.
25. Lebwohl M., Tyring S.K., Hamilton T.K., Toth D., Glazer S., Tawfik N.H. et al. (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349: 2004 2013.
26. Salas A., Shimaoka M., Kogan A.N., Harwood C., von Andrian U.H., Springer T.A. (2004) Rolling adhesion through an extended conformation of integrin αLβ2 and relation to α I and β I-like domain interaction. Immunity 20: 393 406.
27. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C. et al. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7: 687 692.
28. Larson R.S., Davis T., Bologa C., Semenuk G., Vijayan S., Li Y. et al. (2005) Dissociation of I domain and global conformational changes in LFA-1: refinement of small molecule-I domain structure-activity relationships. Biochemistry 44: 4322 4331.
29. Anderson M.E., Siahaan T.J. (2003) Mechanism of binding and internalization of ICAM-1-derived cyclic peptides by LFA-1 on the surface of T cells: a potential method for targeted drug delivery. Pharm Res 20: 1523 1532.
30. Anderson M.E., Tejo B.A., Yakovleva T., Siahaan T.J. (2006) Characterization of binding properties of ICAM-1 peptides to LFA-1: inhibitors of T-cell adhesion. Chem Biol Drug Des 68: 20 28.
31. Gadek T.R., Burdick D.J., McDowell R.S., Stanley M.S., Marsters J.C. Jr, Paris K.J. et al. (2002) Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science 295: 1086 1089.
32. Zimmerman T., Oyarzabal J., Sebastian E.S., Majumdar S., Tejo B.A., Siahaan T.J. et al. (2007) ICAM-1 peptide inhibitors of T-cell adhesion bind to the allosteric site of LFA-1. An NMR characterization. Chem Biol Drug Des 70: 347 353.
33. Yusuf-Makagiansar H., Makagiansar I.T., Siahaan T.J. (2001) Inhibition of the adherence of T-lymphocytes to epithelial cells by a cyclic peptide derived from inserted domain of lymphocyte function-associated antigen-1. Inflammation 25: 203 214.
34. Verkhivker G.M., Bouzida D., Gehlhaar D.K., Rejto P.A., Arthurs S., Colson A.B. et al. (2000) Deciphering common failures in molecular docking of ligand-protein complexes. J Comput Aided Mol Des 14: 731 751.
35. Verkhivker G.M. (2004) Computational analysis of ligand binding dynamics at the intermolecular hot spots with the aid of simulated tempering and binding free energy calculations. J Mol Graph Model 22: 335 348.
36. Verkhivker G.M. (2007) Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity. Proteins 66: 912 929.
37. Verkhivker G.M. (2007) In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures. Biopolymers 85: 333 348.
38. Phillips J.C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E. et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781 1802.
39. McFadyen I.J., Ho J.C., Mosberg H.I., Traynor J.R. (2000) Modifications of the cyclic mu receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]NH2 (Et): effects on opioid receptor binding and activation. J Pept Res 55: 255 261.
40. Anderson M.E., Yakovleva T., Hu Y., Siahaan T.J. (2004) Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides. Bioorg Med Chem Lett 14: 1399 1402.
41. Gursoy R.N., Jois D.S., Siahaan T.J. (1999) Structural recognition of an ICAM-1 peptide by its receptor on the surface of T cells: conformational studies of cyclo (1, 12)-Pen-Pro-Arg-Gly-Gly-Ser-Val-Leu-Val-Thr-Gly-Cys-OH. J Pept Res 53: 422 431.